Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by S. Nikfar
Total Records ( 4 ) for S. Nikfar
  S. Nikfar , R. Rahimi and M. Abdollahi
  Interferon beta (IFNβ) an immunomodulatory agent has been approved for Multiple Sclerosis (MS) patients with a relapsing course. The aim of this meta-analysis was to compare three different formulations of IFNβ including intramuscular IFNβ-1a (Avonex®), subcutaneous IFNβ-1a (Rebif®) and subcutaneous IFNβ-1b (Betaseron or Betaferon) in Relapsing Remitting MS (RRMS). Pubmed, Scopus and Cochrane Central Register of controlled trials were searched for studies comparing efficacy of different formulations of IFNβ in RRMS. Data were collected from 1966 to 2009 (up to July). Mean change in Expanded Disability Status Scale (EDSS) and number of patients with at least one relapse were the key outcomes of interest for assessment of efficacy. Six studies met our criteria and were included. Comparison of Avonex with Rebif yielded a non-significant Relative Risk (RR) of 0.85 (95% CI of 0.57-1.25, p = 0.3954). A non-significant RR of 0.91 (95% CI of 0.75-1.10, p = 0.3378) was obtained when Avonex compared with Betaferon. Comparison of Rebif with Betaferon yielded a significant RR of 0.9 (95% CI of 0.82-1, p = 0.0481). Although, not statistically significant, Rebif or Betaferon work better than Avonex whereas Betaferon was even better than Rebif in management of RRMS.
  S. Nikfar , M. Darvish-Damavandi and M. Abdollahi
  Pouchitis is the most frequent long-term complication of Ileal Pouch-Anal Anastomosies (IPAA) surgery for Ulcerative Colitis (UC) which is a nonspecific inflammation of the ileal reservoir. Its clinical frequency varies depending on the definition and the follow up but is approximately 50% after a decade. Antibiotics and probiotics are currently the most widely accepted treatment in pouchitis patients. Objective of this study was to meta-analyze efficacy of probiotics and antibiotics in the management of pouchitis. All databases specially Pubmed, Web of Science, Scopus, Cochrane and Google Scholar were searched between 1965 and December 2009 and relevant controlled clinical trials were extracted, reviewed and validated according to the study protocol. The outcome of interest was defined by a Pouchitis Disease Activity Index (PDAI)<7. Thirteen clinical trials were included in the meta-analysis. Pooling of the results from eight trials yielded a Relative Risk (RR) of 5.33 with a 95% CI of 2.12-13.35 and a significant RR (p = 0.0004) in all kind of probiotics treatment group in comparison with the placebo group. Summary RR for clinical improvement in six trials was 14.17 with a 95% CI of 1.19-168.93 (p = 0.036) in efficacy of VSL#3 (all doses) comparing to placebo and slightly more effective for VSL#3 (6 g day-1) comparing to placebo with RR of 20.35 with a 95% CI of 6.16-67.22 (p<0.0001). Efficacy of antibiotics comparing to placebo showed a summary RR of 2.68 with a 95% CI of 0.4-17.99 and p = 0.3107 for clinical improvement in three trials. The summary RR for efficacy of ciprofloxacin comparing to metronidazole was 0.68 with a 95% CI of 0.44-1.06 (p = 0.8913). In conclusion, alongside the benefit of probiotics and antibiotics in the management of pouchitis, effects of probiotics and antibiotics on pouchitis vary according to different mixtures of microorganisms strains in probiotics and different spectrums of antibiotics.
  M. Khanavi , H. Azimi , S. Ghiasi , S. Hassani , R. Rahimi , S. Nikfar , Y. Ajani , M.R. Shams-Ardekani and M. Abdollahi
  In the present study, cAMP and cGMP phosphodiesterase inhibitory (PDEI) activities of the ethanolic extracts of nineteen plants of Traditional Iranian Medicine (TIM) with aphrodisiac effects were investigated. The plants were extracted in a similar way and then three concentrations (0. 1, 1, 5 mg mL-1) from each were tested for PDEI activity against control and sildenafil. Among plants tested, 8 including Allium cepa, Trigonella foenum-graecum, Brassica rapa, Alpinia officinarum, Tribulus terrestris, Urtica pilulifera, Linum usitatissimum and Zingiber zerumbet exhibited a significant dose-dependent cAMP-PDEI activity and 6 including A. cepa, A. officinarum, T. terrestris, L. usitatissimum, Withania somnifera and Z. zerumbet gave a remarkable dose-dependent cGMP-PDEI effects in comparison to control. Among tested herbs, Zingiber officinalis and Peganum harmala at dose of 5 mg mL-1 demonstrated better cGMP-PDEI in comparison to sildenafil. The results of this study give idea for discovery of safe and better drugs in management of erectile dysfunction.
  A.H. Abdolghaffari , S. Nikfar , H.R. Rahimi and M. Abdollahi
  Although, positive role of special bacteria in induction of Inflammatory Bowel Disease (IBD) including Ulcerative Colitis (UC) and Crohn’s Disease (CD) have been demonstrated in several studies but the consensus on etiology of IBD and beneficial effect of antibiotics has not been reached yet. And, also, no well-designed clinical trials in this regard have been done yet. This review focuses on various clinical trials which have been done in according to beneficial use of antibiotics in UC and CD from 1978 to date. For this purpose, all electronic databases such as PubMed, Scopus, Google Scholar and Cochrane library were searched. The results of clinical trials suggested that metronidazole, ciprofloxacin or the combinations of these antibiotics are effective in CD. However, ciprofloxacin is the first choice, because it has good coverage on gram negative and anaerobic bacterium which plays an important role in CD. However, there is a controversy on the use of antibiotics in UC and the efficacy of them in long-term treatment of UC is still in doubt. Various antibiotics such as anti-tuberculosis, macrolides (clarithromycin), fluoroquinolones, 5-nitroimidazoles, rifaximin, rifamycin derivatives (rifampin), aminoglycosides (tobramycin), rifabutin, clofazimine, tetracyclines (tetracycline and doxycycline) and vancomycin have been under attention of researchers in the recent years. Furthermore, other antibiotics with lower cost and adverse effects, effectiveness and availability are the third generation of cephalosporins and gentamicin and also penicillin or clindamycin that should be evaluated in future studies.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility